The prognostic B2-Score for metastatic breast cancer: An external evaluation of 852 patients.

1103 Background: The B2-Score is an individual, quantitative assessment of the likelihood of overall survival for advanced breast cancer patients based on routine parameters easily accessible in daily clinical care. Although major progress has been made, the optimal therapeutic management of the individual patient is still unknown. Besides elaborative molecular classification of tumors simple clinical measures such a prognostic score may be helpful to further individualize optimal breast cancer care. This study is a further external evaluation of this score. Methods: This German multicenter [17 certified breast cancer centers] retrospective cohort study called BRENDA (Quality of breast cancer care under evidence-based guidelines) included 10.119 advanced breast cancer patients. In the Cox regression model, hormone receptor (HR) status, the specific site of metastasis, and metastatic-free interval (MFI) were associated with survival from first relapse. Results: Medianage at primary diagnosis was 63 yrs (ra...